Zoetis Inc. (ZTS) — Fair Value Analysis

Base-case fair value (P50): $100.88 · Current price: $78.92 · Verdict: Undervalued

The Verdict on ZTS

Zoetis (ZTS) is currently trading at $81.81, a figure that significantly understates its intrinsic value based on our comprehensive Monte Carlo simulations. Our analysis points to a median fair value (P50) of $112.54, leading to a verdict that ZTS is Deeply Undervalued. This substantial difference represents a +37.6% upside potential from the current market price, making the Healthcare sector company a compelling candidate for re-evaluation. The Monte Carlo framework accounts for thousands of potential forward scenarios, consistently identifying a material undervaluation relative to its current $81.81 trading level.

How ZTS stacks up against Healthcare

Within the competitive Healthcare sector, ZTS is assessed as having an "average" quality tier, reflecting its operational and financial health relative to peers. Despite this classification, the robust quantitative results from our Monte Carlo simulations suggest a significant mispricing in the market. The gap between the current $81.81 share price and the median fair value of $112.54 is substantial, indicating that even an "average" quality company can present a compelling opportunity when its market valuation lags its intrinsic worth. This +37.6% upside highlights a disconnect that warrants investor scrutiny, independent of its relative quality standing.

What this means for investors

For investors considering Zoetis, the pronounced valuation gap between the current price of $81.81 and the median fair value of $112.54 is a primary takeaway. Our FairCurve analysis, driven by sophisticated Monte Carlo simulations, strongly indicates that ZTS is Deeply Undervalued, offering a +37.6% potential return to its calculated P50. This significant upside potential holds true even considering its "average" quality tier within the Healthcare sector, underscoring that intrinsic value can diverge notably from market pricing. While a comprehensive understanding involves reviewing various scenarios, the current $81.81 price clearly stands below its calculated intrinsic worth. To see the full bear/bull distribution and track ZTS's fair value as new fundamentals are released, sign up for a FairCurve account today.